Press release
MeiraGTx Reports Third Quarter 2021 Financial and Operational Results
LONDON and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company,
About this update from Meiragtx Holdings Plc
[{"type":"text","content":"LONDON and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third quarter ended September 30, 2021 and provided an update on recent progress. During the quarter, MeiraGTx continued to progress the Phase 3 Lumeos Trial of botaretigene sparoparvovec, formerly referred to as AAV5-RPGR, in X-linked retinitis pigmentosa (XLRP) with its partner Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, with subjects currently screening. Data from the Phase 1/2 dose escalation study in RPGR patients presented at the EURETINA 2021 Virtual Meeting showed treatment with botaretigene sparoparvovec reverses the course of disease progression when retinal function assessed 12 months following treatment is compared with retinal function in these same subjects up to 48 months prior to treatment. The Company continues to successfully enroll subjects in its AQUAx Phase 1 study for treatment of Grade 2/3 radiation-induced xerostomia with 4 sites open and anticipates completing enrollment in the dose escalation phase of the study by the end of the year. The Company will provide a clinical update from the AQUAx study in early December. At the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Congress the Company presented data on its riboswitch gene regulation platform as well as data from two preclinical programs in ophthalmology targeting two different inherited retinal dystrophies, KCNV2 and GUCY2D. “We continued to make significant progress this quarter advancing our clinical programs,” said Alexandria Forbes, Ph.D., President and Chief Executive Officer of MeiraGTx. “We are equally encouraged by the progress we have made in multiple preclinical programs, including several ophthalmology programs, our AAV-UPF1 program for ALS and our riboswitch gene regulation platform. We look forward to presenting the riboswitch gene regulation platform in further detail at our Research and Development Day in December.” Third Quarter and Recent Corporate and Clinical Development Highlights Botaretigene sparoparvovec for the Treatment of XLRP: Twelve-month clinical data from MeiraGTx’s Phase 1/2 dose-escalation phase of study (MGT009) of botaretigene sparoparvovec were...